A new therapeutic vaccine, GTL001, developed to clear HPV strains 16 and 18 – the types most likely to cause cancer – is being evaluated for safety in a Phase I clinical trial.
A new therapeutic vaccine, GTL001, developed to clear HPV strains 16 and 18 – the types most likely to cause cancer – is being evaluated for safety in a Phase I clinical trial.